Galapagos Delivers Pre-Clinical Candidate Drug in Alliance with GlaxoSmithKline
News Jan 06, 2009
Galapagos NV has announced that it has successfully achieved a pre-clinical candidate drug in its osteoarthritis alliance with GlaxoSmithKline (GSK). Galapagos also reached milestones on other compounds in the alliance, triggering payments totaling €7.6 million to Galapagos. To date, Galapagos has earned a total of €25.5 million in payments from GSK under this alliance.
The pre-clinical candidate drug is a small molecule that meets all the chemical and biological criteria set by GSK for a potential new drug. The candidate was developed by Galapagos against a novel target discovered with Galapagos' proprietary platform. The molecule is now ready for scale up chemistry and comprehensive safety evaluation, with the aim to enter the clinical research phase within a 12-month time frame.
In June 2006, GSK and Galapagos initiated a program to discover and develop disease-modifying drugs for GSK's global R&D organization.
Through the agreement, Galapagos broadened its drug discovery portfolio in the field of osteoarthritis, with the aim to develop candidate drugs through to successful Proof of Concept in clinical research Phase IIa. GSK has exclusive options to further develop and commercialize these compounds on a worldwide basis.
In July 2007, GSK and Galapagos signed an expansion to include two selected GSK targets. In December 2008, the companies further broadened the scope of the alliance through the inclusion of two more drug targets.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019
16th International Conference on Structural Biology
Mar 11 - Mar 12, 2019